Company news

Cytokinetics, Incorporated news in 2020

Cytokinetics, Incorporated's news releases, calls and decks from 2020, newest first.

View company

Cytokinetics Regains European Rights to Omecamtiv Mecarbil

December 22, 2020

Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND

December 13, 2020

Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2

December 8, 2020

Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists

December 6, 2020

Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND

December 2, 2020

Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum

November 30, 2020

Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen

November 22, 2020

Cytokinetics Names Nancy Wysenski to Board of Directors

November 19, 2020

Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020

November 15, 2020

Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine

November 12, 2020

Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020

November 5, 2020

Cytokinetics Reports Third Quarter 2020 Financial Results

November 3, 2020

Cytokinetics to Announce Third Quarter Results on November 4, 2020

October 20, 2020

Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

October 4, 2020

Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals

September 23, 2020

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271

September 22, 2020

Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions

September 16, 2020

Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy

August 17, 2020

Cytokinetics Reports Second Quarter 2020 Financial Results

August 5, 2020

Cytokinetics to Announce Second Quarter Results on August 6, 2020

July 22, 2020

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 20, 2020

Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

July 13, 2020

Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases

July 12, 2020

FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure

May 7, 2020

Cytokinetics Reports First Quarter 2020 Financial Results

May 5, 2020

Cytokinetics to Announce First Quarter Results on May 6, 2020

April 21, 2020

Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic

April 13, 2020

Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

March 29, 2020

Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

March 3, 2020

Cytokinetics Reports Fourth Quarter 2019 Financial Results

March 2, 2020

Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting

February 19, 2020

Cytokinetics to Announce Fourth Quarter Results on March 3, 2020

February 17, 2020

Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

February 5, 2020

Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants

January 21, 2020

Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

January 12, 2020

Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

January 5, 2020

Decks in 2020